The aim of this randomized controlled trial is to compare the efficacy of oral dydrogesterone vs. micronized vaginal progesterone for luteal phase support in frozen-thawed embryo transfer cycles.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Vaginal progesterone gel 90 mg once a day for luteal phase support
Memorial Şişli Hospital
Istanbul, Şişli, Turkey (Türkiye)
RECRUITINGOngoing pregnancy rate
Presence of at least one live fetus at the end of the 12th gestational week
Time frame: 12 weeks after the last menstrual period of the patient
Clinical pregnancy rate
Presence of an intrauterine gestational sac with fetal heart beat at 7th week of gestation
Time frame: 6-7 weeks after the last menstrual period of the patient
Implantation rate
Percentage of gestational sacs compared to the number of embryos transferred
Time frame: 5 weeks after the last menstrual period of the patient
Biochemical pregnancy
Positive serum beta HCG test performed 10 days after embryo transfer
Time frame: 10 days after embryo transfer
Biochemical miscarriage
pregnancy loss before ultrasonographic detection of an intrauterine gestational sac
Time frame: before 5th gestational week
Clinical miscarriage
pregnancy loss after ultrasonographic detection of an intrauterine gestational sac
Time frame: after 5th gestational week
headache rate
Time frame: 6-7 weeks after the last menstrual period of the patient
interference with coitus rate
Time frame: 6-7 weeks after the last menstrual period of the patient
somnolence rate
Time frame: 6-7 weeks after the last menstrual period of the patient
dizziness rate
Time frame: 6-7 weeks after the last menstrual period of the patient
nausea/vomiting rate
Time frame: 6-7 weeks after the last menstrual period of the patient
vaginal discharge rate
Time frame: 6-7 weeks after the last menstrual period of the patient
perineal irritation rate
Time frame: 6-7 weeks after the last menstrual period of the patient
abdominal pain rate
Time frame: 6-7 weeks after the last menstrual period of the patient
mastalgia rate
Time frame: 6-7 weeks after the last menstrual period of the patient
vaginal bleeding rate
Time frame: 6-7 weeks after the last menstrual period of the patient
interference with intercourse rate
Time frame: 6-7 weeks after the last menstrual period of the patient
overall satisfaction score
patient satisfaction from the drug used measured on a 1-5 scale
Time frame: 6-7 weeks after the last menstrual period of the patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.